What is our Type 2 Diabetes (T2D) test?
The MyOme Integrated Polygenic Risk Score™ (iPRS™) for Type 2 Diabetes combines whole-genome insights with clinical factors—such as age, sex, BMI, blood pressure, cholesterol, and lifestyle—to provide a person’s absolute 10-year risk of developing T2D.
The MyOme Integrated Polygenic Risk Score™ (iPRS™) for Type 2 Diabetes combines whole-genome insights with clinical factors—such as age, sex, BMI, blood pressure, cholesterol, and lifestyle—to provide a person’s absolute 10-year risk of developing T2D. This integrated approach is more accurate than clinical factors alone, enabling earlier and more personalized prevention strategies. The test has been validated across multiple ancestries to ensure broad applicability.
Who is the Type 2 Diabetes (T2D) test for?
The iPRS T2D test is intended for individuals aged 35–70 who do not already have Type 2 Diabetes or use insulin/antidiabetic medications. By providing a clear and personalized risk estimate, the test helps individuals and their providers make informed decisions about screening, prevention, and lifestyle changes—empowering them to reduce their risk or delay the onset of disease.